News Sentiment

LPCN sentiment intelligence

Lipocine Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.41 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 41

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+0.8% over one week, +6.6% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Lipocine Inc. (LPCN) Holds Near Support After Modest Gain, Resistance in Focus - Bull Pennant

Market Reaction

Balanced read

49/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction 0.8% Price digesting
Trend fit Trend inactive 6.6% over four weeks
Fair value -43.8% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 36
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 41
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 12
Stock Titan 8
Market source 7
TradingKey 5
Investing.com 4
PR Newswire 3
Investing.com UK 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 24
Earnings 19
Regulatory and legal 3
Analyst action 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-49 of 49
TradingView Direct company coverage

Lipocine Phase 3 LPCN 1154 Data Accepted for Oral Presentation at 2026 ASCP Meeting

Lipocine announced that its Phase 3 LPCN 1154 data has been accepted for an oral presentation at the 2026 ASCP Annual Meeting. The presentation will highlight LPCN 1154's potential as a rapid-acting, at-home therapy for postpartum depression (PPD) with improved tolerability. A po

Tone
Positive 76/100
Event
Market update
Published
19 May 2026 13:09
Source
TradingView
Associated Press Direct company coverage

Lipocine: Q1 Earnings Snapshot

Tone
Neutral 50/100
Event
Earnings
Published
07 May 2026 18:11
Source
Associated Press